UBS analyst Eliana Merle lowered the firm’s price target on CureVac (CVAC) to $12 from $13 and keeps a Buy rating on the shares. CureVac’s mRNA platform and oncology pipeline remain underappreciated, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVAC:
- CureVac’s Uncertain Prospects Amid Operational Restructuring and Pipeline Challenges
- CureVac’s Financial Resilience Amid Operational Challenges and Clinical Trial Uncertainties: A Hold Rating Analysis
- CureVac N.V. Earnings Call: Financial Strength Amid Challenges
- CureVac’s Promising Pipeline and Legal Wins Justify Buy Rating
- CureVac Stock (CVAC) Dips Despite Promising Treatment Pipeline